This content is provided by Amgen.
Divided into 3 sections, this presentation provides insight into the complexities of developing and manufacturing biologics and discusses considerations for the development of biosimilars.
Please click the image below to view the presentation.
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More